OBJECTIVE: To review the pharmacology, pharmacokinetics, and pivotal clinical trials for
bevacizumab, emphasizing its use in colorectal cancer. DATA SOURCES: A …

BACKGROUND:: Bevacizumab is a recombinant humanized monoclonal antibody that was
approved by the US Food and Drug Administration (FDA) in February 2004 for use as part of …

Bevacizumab is a humanised monoclonal antibody that inhibits vascular endothelial growth
factor (VEGF), the key mediator of tumour angiogenesis, and has been shown to improve …

Bevacizumab (Avastin®) is a recombinant, humanized monoclonal antibody against
vascular endothelial growth factor (VEGF) that is used to inhibit VEGF function in vascular …

The importance of vascular endothelial growth factor (VEGF) as a regulator of normal and
tumor blood vessel growth has been increasingly characterized over the past two decades …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the clinical development of bevacizumab. Summarize the clinical trials conducted …

Introduction: Angiogenesis is a key factor in the development of aberrant blood vessels
required for malignant growth, invasion and progression. Inhibiting VEGF is by far the most …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the clinical experience of bevacizumab in colorectal cancer. Explain the relevant …

Purpose. The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy,
adverse effects, and dosage and administration of bevacizumab in patients with colorectal …

Purpose. The pharmacology, pharmacokinetics, preclinical and clinical experience to date,
and clinical concerns in monitoring patients receiving bevacizumab, recombinant …